Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026, providing an opportunity to discuss the company's recent milestones and strategic direction. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach. The presentations and meetings come at a pivotal time for Tonix, which recently received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The approval of TONMYA marks a significant milestone, as it addresses a condition that affects millions of patients worldwide and has seen limited therapeutic innovation. Tonix’s CNS commercial infrastructure also supports its marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Beyond its commercial portfolio, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, expanding the drug's possible applications. The company's CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The investor conferences provide a platform for Tonix to communicate its progress and future plans to the financial community. For more details on the presentations, the full press release is available at https://ibn.fm/TToz2. Investors and stakeholders can also stay updated via the company's newsroom at https://ibn.fm/TNXP. The participation in these conferences underscores Tonix's commitment to transparency and engagement with the investment community as it navigates its commercial launch and pipeline development.
